Company / Revenue
Altimmune, Inc. Revenue History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$41.0K
FY2025
5-year range
-$68.0K / $8.2M
FY2021-FY2025
Trend
-90.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from -$68,000 in FY2023 to $21M in FY2011.
Based on SEC 10-K filings.
$41,000 in FY2025 with a 5-year CAGR of -62.9%.
Improved from -$68,000 to $41,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -79.0%
- 5-Year CAGR
- -62.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -62.9%, indicating a declining trend.
- In FY2025, revenue decreased 90.4% year-over-year.
- Peak revenue was recorded in FY2011.
- Lowest revenue in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.0K | -90.4% |
| FY2024 | $426.0K | +726.5% |
| FY2023 | -$68.0K | -101.5% |
| FY2022 | $4.4M | -46.1% |
| FY2021 | $8.2M | +41.1% |
| FY2020 | $5.8M | -43.8% |
| FY2019 | $10.3M | -3.8% |
| FY2018 | $10.7M | +231.8% |
| FY2017 | $3.2M | -84.6% |
| FY2011 | $21.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026